114474-04-3

Basic information

• Product Name: methyl 2-(4-hydroxy-2-methylphenyl)acetate
• Synonyms: methyl 2-(4-hydroxy-2-methylphenyl)acetate;4-hydroxy-2-Methylphenylacetic acid Methyl ester
• CAS NO: 114474-04-3
• Molecular Formula: C₁₀H₁₂O₃
• Molecular Weight: 180
• Mol File: 114474-04-3.mol

Chemical Properties

• Boiling Point: 297.0±25.0 °C(Predicted)
• Appearance: /
• Density: 1.148±0.06 g/cm3(Predicted)
• PKA: 9.88±0.18(Predicted)
• CAS DataBase Reference: methyl 2-(4-hydroxy-2-methylphenyl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(4-hydroxy-2-methylphenyl)acetate(114474-04-3)
• EPA Substance Registry System: methyl 2-(4-hydroxy-2-methylphenyl)acetate(114474-04-3)

Safety Data

• Hazardous Substances Data: 114474-04-3(Hazardous Substances Data)

Upstream product

• 30888-94-9 methyl 2-(4-methoxy-2-methylphenyl)acetate 
• 223406-97-1 methyl [4-(benzyloxy)-2-methylphenyl]acetate 
• 1265683-76-8 2-(4-hydroxy-2-methylphenyl)-2-oxoethyl formate 
• 74-88-4 methyl iodide 
• 41877-16-1 2-bromo-1-(4-hydroxy-2-methylphenyl)-1-ethanone 
• 875-59-2 4'-hydroxy-2'methylacetophenone 

Downstream Products

• 29336-53-6 4-hydroxy-2-methylphenylacetic acid 

Relevant articles and documents

The power of solvent in altering the course of photorearrangements

A clean bifurcation between two important photochemical reactions through competition of a triplet state Type II H-abstraction reaction with a photo-Favorskii rearrangement for (o/p)-hydroxy-o-methylphenacyl esters that depends on the water content of the solvent has been established. The switch from the anhydrous Type II pathway that yields indanones to the aqueous-dependent pathway producing benzofuranones occurs abruptly at low water concentrations (～8%). The surprisingly clean yields suggest that such reactions are synthetically promising.

FURAN OR THIOPHENE DERIVATIVE AND MEDICINAL USE THEREOF

The present invention provides a compound represented by the formula (I): [wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, p is 0, 1 or 2, and when p is 2, each R may be the same or different, R1 is a hydrogen atom or an optionally substituted hydrocarbon group, R2 is an optionally substituted aromatic group, Ring A is an optionally substituted monocyclic aromatic ring or optionally substituted bicyclic aromatic fused ring, X1 is an oxygen atom or a sulfur atom, X2 is a bond, an oxygen atom or -S(O)n- (wherein n is 0, 1 or 2), Y is a bond, an oxygen atom, -S(O)m-, -C(=O)-N(R3)- or -N(R3)-C(=O)- (R3 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2), M1, M2 and M3 may be the same or different and are each independently a bond or an optionally substituted divalent aliphatic hydrocarbon group, and M4 is an optionally substituted divalent aliphatic hydrocarbon group] or a salt thereof, which is useful as a prophylactic and/or therapeutic agent for lipid metabolism abnormality, arteriosclerotic disease and sequelae thereof, diabetes mellitus and the like.

BICYCLIC DERIVATIVES AS PPAR MODULATORS

The present invention is directed to compounds represented by the following structural formula, Formula (I), and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: (a) R2 is selected from the group consisting of C0-C8 alkyl and C1-4- heteroalkyl; (b) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (c) U is an aliphatic linker wherein one carbon atom of the aliphatic linker is optionally replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with from one to four substituents each independently selected from R30; (d) Y is selected from the group consisting of C, O, S, NH and a single bond; and (e) E is C(R3)(R4)A or A.

FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS

The present invention is directed to compounds represented by the following structural formula, Formula I: wherein (a) X is selected from the group consisting of a single bond, O, S. S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of C, O, S, NH and a single bond; (d) E is C(R3) (R4)A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamidek, sulfonamide and acylsulfonamide; (e) B is selected from the group consisting of S, O, C, and N; (f) Z is selected from the group consisting of N and C; with the proviso that when B is C then Z is N.

THIOPHENE DERIVATIVE PPAR MODULATORS

The present invention is directed to compounds represented by the following structural formula, Formula I: and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: (a) X is selected from the group consisting of O, S, S(O)2, N, and a bond; (b) U is an aliphatic linker wherein one carbon atom of the aliphatic linker may be replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with R30; (c) Y is selected from the group consisting of C, O, S, NH and a single bond; and (d) E is C(R3)(R4)A or A.